# Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

> **NCT01289431** · PHASE2 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 236 (actual)

## Conditions studied

- Conjunctivitis, Allergic

## Interventions

- **DRUG:** Mapracorat
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT01289431
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2020-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01289431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01289431, "Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01289431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*